Dr Reddy’s acquire Eton Pharma's injectable products for $ 50 mn

For these and many other reasons, I believe we are well-positioned to integrate the portfolio and grow the business, Marc Kikuchi, Chief Executive Officer, North America Generics, Dr Reddys said.The value of total addressable market for these products in the USA is approximately USD 174 million for the calendar year ending in April 2022, Dr Reddys said quoting market figures.


PTI | Hyderabad | Updated: 24-06-2022 18:36 IST | Created: 24-06-2022 18:07 IST
Dr Reddy’s acquire Eton Pharma's injectable products for $ 50 mn
Representative Image Image Credit: ANI
  • Country:
  • India

Dr. Reddy's Laboratories Ltd on Friday announced that it has acquired a portfolio of branded and generic injectable products from USA-based Eton Pharmaceuticals, Inc for USD 50 million. A press release from the Indian drug maker said the portfolio includes the Biorphen (phenylephrine hydrochloride) injection and Rezipres (ephedrine hydrochloride) injection NDAs (New Drug Applications) with nine separate combinations of strengths and presentations and one first-to-file approved ANDA ( abbreviated new drug application) for Cysteine Hydrochloride for the USA.

One strength each of Biorphen and Rezipres are currently commercially available in the USA. The acquisition will complement Dr. Reddy's USA's institutional business with limited competition in injectable products, it said.

Under the terms of the agreement, Dr. Reddy acquired the Eton portfolio for an upfront payment of approximately USD 5 million in cash, besides contingent payments of up to USD 45 million. The acquisition supports Dr. Reddy's efforts to accelerate and expand affordable medications for patients, the release said.

''Long before the COVID-19 pandemic, there have been concerns about access to some critical care products for hospitals and health systems. This acquisition provides our North American organization with a foundational footprint to help address products that are not always readily available for patients. For these and many other reasons, I believe we are well-positioned to integrate the portfolio and grow the business,'' Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy's said.

The value of the total addressable market for these products in the USA is approximately USD 174 million for the calendar year ending in April 2022, Dr. Reddy's said quoting market figures.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Give Feedback